Journal of the American Heart Association · 2026
Dexamethasone Nonsuppression in Primary Aldosteronism: Associations With Adrenal Imaging Findings.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiang-Tao, Zeng Qing-Tian, Lin Zi-Xin, Zhang Hong-Jing, Wu Meng-Bo, Zhang Huang, Wang Rui, Shuai Wen-Liang, Zhang Hang-Cheng, Yang Jiao, Xiong Hong-Liang, Dong Yi-Fei
Аннотация
BACKGROUND: The 1-mg dexamethasone suppression test (DST) nonsuppression is increasingly recognized beyond adrenal incidentaloma, but its prevalence and clinical significance in patients evaluated for primary aldosteronism (PA) remain unclear, particularly in those without adrenal nodules.
METHODS: In this prospective observational study, consecutive patients with hypertension suspected of PA underwent standardized hormonal evaluation, including the 1-mg DST. DST nonsuppression was defined as post-DST serum cortisol >1.8 μg/dL in the absence of overt Cushing's syndrome. Patients were classified as non-PA or confirmed PA and further stratified by adrenal nodules status on computed tomography. Associations with DST nonsuppression were examined using multivariable logistic regression and propensity score-based analyses, with overlap weighting as the primary approach.
RESULTS: Among 883 patients who completed the 1-mg DST, DST nonsuppression was observed in 12.2%. Its prevalence showed an increasing pattern across groups, being lowest in individuals without PA, intermediate in patients with PA without adrenal nodules, and highest in those with adrenal nodules. Adrenal nodules were independently associated with DST nonsuppression (odds ratio, 2.68 [95% CI, 1.01-7.12]), with consistent findings across propensity score-based analyses. Among patients with PA without adrenal nodules, DST nonsuppression was associated with lower estimated glomerular filtration rate and a higher prevalence of chronic kidney disease.
CONCLUSIONS: In the high-risk population with PA, DST nonsuppression was not randomly distributed across predefined groups and was independently associated with adrenal nodules. Even in the absence of adrenal nodules, DST nonsuppression was associated by less favorable renal markers, supporting its consistent association with clinical characteristics in patients with PA, rather than implying a distinct biochemical characteristic.
METHODS: In this prospective observational study, consecutive patients with hypertension suspected of PA underwent standardized hormonal evaluation, including the 1-mg DST. DST nonsuppression was defined as post-DST serum cortisol >1.8 μg/dL in the absence of overt Cushing's syndrome. Patients were classified as non-PA or confirmed PA and further stratified by adrenal nodules status on computed tomography. Associations with DST nonsuppression were examined using multivariable logistic regression and propensity score-based analyses, with overlap weighting as the primary approach.
RESULTS: Among 883 patients who completed the 1-mg DST, DST nonsuppression was observed in 12.2%. Its prevalence showed an increasing pattern across groups, being lowest in individuals without PA, intermediate in patients with PA without adrenal nodules, and highest in those with adrenal nodules. Adrenal nodules were independently associated with DST nonsuppression (odds ratio, 2.68 [95% CI, 1.01-7.12]), with consistent findings across propensity score-based analyses. Among patients with PA without adrenal nodules, DST nonsuppression was associated with lower estimated glomerular filtration rate and a higher prevalence of chronic kidney disease.
CONCLUSIONS: In the high-risk population with PA, DST nonsuppression was not randomly distributed across predefined groups and was independently associated with adrenal nodules. Even in the absence of adrenal nodules, DST nonsuppression was associated by less favorable renal markers, supporting its consistent association with clinical characteristics in patients with PA, rather than implying a distinct biochemical characteristic.